- While much of the attention paid to Quincy Bioscience
centers on the compound it is developing from jellyfish, it is the company's emerging business model that may put other medical treatments 25,000 leagues under the sea.
Quincy Bioscience is based in Madison's University Research Park, but it derives its research supp......Full article >>>
ept/Psychology/faculty/moyer.html">James Moyer, said lab results thus far indicate the protein, aequorin, is much more "neuroprotective" than existing treatments. According to Underwood, aequorin has helped anywhere from 28 to 45 percent of brain cells survive, without toxicity, after being subjected to the lab equivalent of a stroke.
Ninety-nine percent of the body's calcium is conta......Full article >>>
sing the role future funding will play.
The company expects to have a pharmaceutical product on the market in seven years. It will seek to raise private equity to develop aequorin-based therapies for each disease it targets, starting with strokes and followed (not necessarily in this order) by Alzheimer's, Parkinson's, Huntington's, and Amyotrophic Lateral Sclerosis (ALS), also known as ......Full article >>>
Quincy's science and the business model may take it farther than most biotechs, but it's the Milwaukee-Madison connection that intrigues Leonhart and others that envision a robust IQ Corridor. "It kind of shows that the research in this state can be created anywhere and be successfully planted elsewhere," he said.
......Full article >>>
Source:wistechnology.com By Joe Vanden Plas 08/31/06Related biology technology :1
. Biotech officials praise focus of new venture fund2
. Biotech executive books a career flight thats closer to home3
. Gala Biotech among companies sold for $3.3 billion4
. Biotech with Madison ties raises $21M in capital5
. Biotech firm uses live heart tissue in drug screens6
. Biotech talent drew venture-funded firm to Madison7
. 42 days until the 2006 Olympics of Biotechnology in Chicago8
. Biotech crops gaining acceptance, but their full promise has yet to be fulfilled9
. Biotech leads list of top U.S. companies to work for10
. Biotech flourishes in 2005 while Big Pharma is on the decline11
. Though Weakening, Biotech IPO Market Still Viable, Burril & Co. Says